bluebird bio v. Sloan-Kettering: Appeal Dismissed in Gene Therapy Patent Case

Introduction: A Consensual Exit from the Federal Circuit

In a case that drew attention from gene therapy developers and biotech patent practitioners alike, bluebird bio, Inc. v. Sloan-Kettering Institute for Cancer Research (Case No. 24-2016) concluded at the U.S. Court of Appeals for the Federal Circuit on August 6, 2025 — not with a ruling on the merits, but with a voluntary dismissal agreed upon by both parties. Filed on June 27, 2024, and resolved in 405 days, the appeal centered on the patentability of a vector encoding human globin genes used in treating hemoglobinopathies such as sickle cell disease and beta-thalassemia.

The case involved U.S. Patent No. 8,058,061 B2 — a foundational gene therapy patent — and turned on an invalidity and cancellation challenge. For patent attorneys, IP professionals, and R&D leaders operating in the gene therapy space, this dismissal carries strategic signal even in the absence of a substantive ruling. When well-resourced parties walk away from a Federal Circuit appeal by mutual agreement, the underlying dynamics deserve careful analysis.

Case Overview

The Parties

The Patent at Issue

• • Patent Number: US 8,058,061 B2 (Application No. 12/433,412)
• • Technology Area: Gene therapy — specifically, a vector encoding a human globin gene
• • Claimed Application: Treatment of hemoglobinopathies, including sickle cell disease and beta-thalassemia
• • Verdict Cause: Patentability — Invalidity/Cancellation Action

The ‘061 patent covers vector constructs critical to delivering functional globin genes into hematopoietic stem cells, a cornerstone of lentiviral gene therapy platforms.

Legal Representation

Both firms represent elite patent litigation capability, underscoring the commercial stakes attached to this dispute.

• • Plaintiff (bluebird bio): Paul Hastings, LLP — Attorneys Daniel Zeilberger, Eric William Dittmann, Krystina L. Ho, Max H. Yusem, and Naveen Modi
• • Defendant (Sloan-Kettering): Wilmer Cutler Pickering Hale & Dorr LLP — Attorneys Annaleigh E. Curtis, Robert J. Gunther, and Timothy A. Cook

Litigation Timeline & Procedural History

The appeal (Case No. 24-2016) was filed on June 27, 2024, before the U.S. Court of Appeals for the Federal Circuit, the exclusive appellate venue for U.S. patent matters arising from the District of Columbia circuit. The case closed on August 6, 2025, reflecting a total duration of 405 days from filing to dismissal.

The appeal reached the Federal Circuit following a lower-level proceeding involving an invalidity and cancellation challenge to US 8,058,061 B2 — suggesting the dispute originated in a USPTO post-grant proceeding (such as an inter partes review) or district court action before escalating to the appellate level. The Federal Circuit, as the nation’s specialized patent appellate court, is the definitive forum for such patentability challenges.

No chief judge information was disclosed in the case record. Specific intermediate milestones — including briefing schedules, oral argument dates, or panel compositions — were not available in the provided case data.

The 405-day duration before voluntary dismissal suggests the parties engaged in substantive pre-dismissal negotiations, potentially including licensing discussions, business restructuring considerations, or strategic reassessment of litigation economics.

The Verdict & Legal Analysis

Outcome

The Federal Circuit’s order is direct: pursuant to Federal Rule of Appellate Procedure 42(b), the proceeding was dismissed by agreement of the parties, with each side bearing its own costs. No damages were awarded. No injunctive relief was granted or denied. No merits ruling on the invalidity or cancellation challenge was issued.

This is a stipulated dismissal — a negotiated exit — not an adverse judgment for either party.

Verdict Cause Analysis

The underlying legal theory was a patentability challenge: invalidity and/or cancellation of US 8,058,061 B2. While the specific grounds (e.g., anticipation under 35 U.S.C. § 102, obviousness under § 103, or enablement under § 112) were not disclosed in the available case record, invalidity challenges to foundational gene therapy vector patents frequently implicate:

• • Prior art disputes over early lentiviral vector constructs
• • Written description and enablement challenges given the complexity of gene therapy claim scopes
• • Obviousness arguments tying together prior art constructs with known globin gene sequences

The mutual agreement to dismiss — with each side absorbing its own costs — is legally neutral on the merits but practically significant. It eliminates the risk of a precedential Federal Circuit ruling that could affect either party’s broader patent portfolio or licensing posture.

Legal Significance

Because the appeal was dismissed under Rule 42(b) without a merits decision, no binding precedent was established. The ‘061 patent’s validity status as determined in the underlying proceeding remains operative, but the Federal Circuit issued no new guidance on gene therapy patent claim construction, enablement standards, or validity doctrine in this instance.

This outcome is notable precisely because the Federal Circuit did not rule. For gene therapy patent practitioners, the absence of appellate precedent here means that foundational questions about vector-encoding patent scope — relevant to hemoglobinopathy treatment claims broadly — remain unresolved at the circuit level.

Strategic Takeaways

For Patent Holders: A consensual Federal Circuit dismissal can preserve licensing leverage by avoiding an adverse validity ruling. When a patent’s commercial value depends on licensing rather than litigation victory, protecting the patent from a final invalidation order — even by walking away from an appeal — may be the strategically superior outcome.

For Accused Infringers: Securing a favorable lower-tribunal ruling on invalidity, then negotiating a dismissal without binding appellate confirmation, leaves the challenger’s position legally consolidated but without precedential armor. If the underlying invalidity finding stands, it serves the challenger’s purposes even without Federal Circuit affirmation.

For R&D Teams: Freedom-to-operate analyses in the hemoglobinopathy and gene therapy space must account for the fact that the ‘061 patent’s claim scope was contested but not definitively resolved at the appellate level. FTO assessments should incorporate the procedural history of this patent, including any PTAB or district court findings from the underlying proceeding.

Industry & Competitive Implications

The bluebird bio v. Sloan-Kettering dismissal occurs against a backdrop of intense competitive and financial pressure in the gene therapy sector. bluebird bio has faced significant business headwinds, including FDA review cycles, commercial launch challenges for its sickle cell and beta-thalassemia therapies, and financing pressures — all of which may have influenced the calculus around continued appellate litigation.

For Sloan-Kettering, whose IP licensing revenues support ongoing research, the resolution of this dispute — on whatever terms the parties negotiated privately — affects the commercialization pathway for vector technology derived from its research programs.

More broadly, this case reflects an industry-wide trend: biotech patent disputes increasingly resolve through negotiated exits rather than full merits adjudication, particularly where both parties have exposure (validity challenges cut both ways), and where ongoing licensing relationships or co-development arrangements may be more valuable than a litigation win.

Companies in the gene therapy, cell therapy, and rare disease therapeutic space should monitor the ‘061 patent’s post-proceeding status and any licensing terms that may emerge, as vector encoding technology remains a high-stakes IP battleground.

FAQ

What patent was at issue in bluebird bio v. Sloan-Kettering (Case 24-2016)?

The case involved U.S. Patent No. 8,058,061 B2 (Application No. 12/433,412), covering a vector encoding a human globin gene and its use in treating hemoglobinopathies.

Why was the Federal Circuit appeal dismissed?

The parties agreed to dismiss the proceeding under Federal Rule of Appellate Procedure 42(b), with each side bearing its own costs. No merits ruling was issued.

How does this dismissal affect gene therapy patent litigation?

Because no Federal Circuit opinion was issued, no binding precedent on the validity or claim scope of this gene therapy patent was established, leaving key legal questions unresolved at the appellate level.

📩 Subscribe for patent litigation updates in gene therapy and biotech IP. Explore related Federal Circuit cases in the gene therapy patent space, or search USPTO records for US 8,058,061 B2 for full prosecution history.
For case-specific analysis or freedom-to-operate assessments in the hemoglobinopathy therapeutic space, contact a qualified IP counsel.